Death receptors and melanoma resistance to apoptosis.

PubWeight™: 1.51‹?› | Rank: Top 4%

🔗 View Article (PMID 12789291)

Published in Oncogene on May 19, 2003

Authors

Vladimir N Ivanov1, Anindita Bhoumik, Ze'ev Ronai

Author Affiliations

1: Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.

Articles citing this

MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol (2012) 1.59

Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. J Invest Dermatol (2013) 1.56

NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55

Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A (2004) 1.46

Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42

Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21

Function and regulation of retinoic acid-inducible gene-I. Crit Rev Immunol (2010) 1.15

Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res (2007) 1.14

Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10

Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10

Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia (2007) 1.06

Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem (2004) 1.06

Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer (2008) 1.04

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03

Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem (2005) 1.02

Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci (2010) 0.98

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg (2004) 0.95

Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res (2010) 0.95

Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One (2013) 0.95

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer (2010) 0.93

Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther (2014) 0.92

Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol (2004) 0.90

Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol (2010) 0.89

Cytokine-induced tumor suppressors: a GRIM story. Cytokine (2010) 0.88

(-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle (2009) 0.88

Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res (2010) 0.88

Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther (2009) 0.88

Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res (2006) 0.87

Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J Cell Biochem (2011) 0.83

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs (2006) 0.83

Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis. Apoptosis (2012) 0.82

Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys (2014) 0.81

Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia (2010) 0.81

Innovative Therapies against Human Glioblastoma Multiforme. ISRN Oncol (2011) 0.81

Association of a Methanol Extract of Rheum undulatum L. Mediated Cell Death in AGS Cells with an Intrinsic Apoptotic Pathway. J Pharmacopuncture (2015) 0.80

Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 cell line. Biomed Res Int (2013) 0.80

Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget (2015) 0.80

Role of nanotechnology and gene delivery systems in TRAIL-based therapies. Ecancermedicalscience (2016) 0.79

Bim and VDAC1 are hierarchically essential for mitochondrial ATF2 mediated cell death. Cancer Cell Int (2015) 0.79

Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway. Cancer Biol Ther (2011) 0.78

Apoptosis of AGS human gastric adenocarcinoma cells by methanolic extract of Dictamnus. Pharmacogn Mag (2015) 0.77

Nuclear receptor subfamily 4, group A, member 1 inhibits extrinsic apoptosis and reduces caspase-8 activity in H2O2-induced human HUC-F2 fibroblasts. Redox Rep (2014) 0.76

Ethanol Extract of Oldenlandia diffusa - an Effective Chemotherapeutic for the Treatment of Colorectal Cancer in Humans: -Anti-Cancer Effects of Oldenlandia diffusa. J Pharmacopuncture (2016) 0.75

The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma. Front Pharmacol (2017) 0.75

RACK1 promotes hepatocellular carcinoma cell survival via CBR1 by suppressing TNF-α-induced ROS generation. Oncol Lett (2016) 0.75

Expression and functions of galectin-7 in human and murine melanomas. PLoS One (2013) 0.75

Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity. Cell Death Dis (2016) 0.75

Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75

Articles by these authors

Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77

Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest (2009) 3.17

The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02

Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J (2004) 2.50

Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell (2004) 2.43

A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One (2012) 2.24

Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03

Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer (2010) 1.76

RNF5, a RING finger protein that regulates cell motility by targeting paxillin ubiquitination and altered localization. Mol Cell Biol (2003) 1.75

Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J Biol Chem (2007) 1.61

RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell (2005) 1.59

Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress. Cell Cycle (2011) 1.59

Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci U S A (2007) 1.58

ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene (2003) 1.57

Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A (2004) 1.46

REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep (2009) 1.44

Stress-induced decrease in TRAF2 stability is mediated by Siah2. EMBO J (2002) 1.44

The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proc Natl Acad Sci U S A (2008) 1.42

p53-Mdm2--the affair that never ends. Carcinogenesis (2002) 1.40

ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol Cell (2005) 1.39

An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res (2003) 1.31

The ubiquitin ligase Siah2 and the hypoxia response. Mol Cancer Res (2009) 1.29

A role for ATF2 in regulating MITF and melanoma development. PLoS Genet (2010) 1.28

ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle (2008) 1.27

RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol Cell Biol (2006) 1.27

Regulation of p53 localization and activity by Ubc13. Mol Cell Biol (2006) 1.26

Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A (2008) 1.26

Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res (2007) 1.20

FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol (2003) 1.20

The small ubiquitin-like modifier (SUMO) is required for gonadal and uterine-vulval morphogenesis in Caenorhabditis elegans. Genes Dev (2004) 1.20

Ubiquitin chains in the ladder of MAPK signaling. Sci STKE (2005) 1.17

Ubiquitin and SUMO systems in the regulation of mitotic checkpoints. Trends Biochem Sci (2006) 1.15

The LIM domain protein UNC-95 is required for the assembly of muscle attachment structures and is regulated by the RING finger protein RNF-5 in C. elegans. J Cell Biol (2004) 1.14

Meiotic regulation of the CDK activator RINGO/Speedy by ubiquitin-proteasome-mediated processing and degradation. Nat Cell Biol (2006) 1.12

ATF2 on the double - activating transcription factor and DNA damage response protein. Pigment Cell Res (2007) 1.12

Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem (2006) 1.11

Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene (2004) 1.10

Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10

Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity (2006) 1.08

Emerging roles of E3 ubiquitin ligases in autophagy. Trends Biochem Sci (2013) 1.07

Functional specialization in proline biosynthesis of melanoma. PLoS One (2012) 1.06

The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS One (2008) 1.05

Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res (2004) 1.05

Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem (2001) 1.04

Regulation of 2-oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah. J Biol Chem (2004) 1.04

Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem (2005) 1.02

SUMO in cancer--wrestlers wanted. Cancer Biol Ther (2002) 1.01

Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem J (2007) 1.01

CREB, ATF, and AP-1 transcription factors regulate IFN-gamma secretion by human T cells in response to mycobacterial antigen. J Immunol (2008) 0.99

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res (2009) 0.98

Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle (2006) 0.98

Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res (2007) 0.98

Mdm2: A regulator of cell growth and death. Adv Cancer Res (2003) 0.97

Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. Cancer Res (2012) 0.97

c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem (2003) 0.96

c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem (2009) 0.94

Regulation of c-myc stability by selective stress conditions and by MEKK1 requires aa 127-189 of c-myc. Oncogene (2002) 0.93

Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci U S A (2004) 0.93

JAMP, a Jun N-terminal kinase 1 (JNK1)-associated membrane protein, regulates duration of JNK activity. Mol Cell Biol (2005) 0.92

GST function in drug and stress response. Drug Resist Updat (1999) 0.90

Fbx8 makes Arf6 refractory to function via ubiquitination. Mol Biol Cell (2007) 0.90

Transformation/transcription domain-associated protein (TRRAP)-mediated regulation of Wee1. Genetics (2010) 0.89

Autophosphorylation properties of inactive and active JNK2. Cell Cycle (2007) 0.89

JAMP optimizes ERAD to protect cells from unfolded proteins. Mol Biol Cell (2008) 0.88

Requirements for PKC-augmented JNK activation by MKK4/7. Int J Biochem Cell Biol (2007) 0.88

Siah: new players in the cellular response to hypoxia. Cell Cycle (2004) 0.87

Balancing Mdm2 - a Daxx-HAUSP matter. Nat Cell Biol (2006) 0.86

Radiation Sensitivity and Tumor Susceptibility in ATM Phospho-Mutant ATF2 Mice. Genes Cancer (2010) 0.85

The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem (2003) 0.85

Melanoma-initiating cells: a compass needed. EMBO Rep (2009) 0.85

Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2. Oncogene (2005) 0.82

Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate stress responses. Sci Signal (2014) 0.82

Roadmap for new opportunities in melanoma research. Semin Oncol (2007) 0.81

Muscle-epidermis interactions affect exoskeleton patterning in Caenorhabditis elegans. Dev Dyn (2007) 0.80

RAF-isotype switching: from B to C through PDE. Nat Struct Mol Biol (2011) 0.78

SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell (2002) 0.77

A new function for p53 ubiquitination. Cell (2006) 0.77

Tricking melanoma to self-digest: a deal of a meal! Cancer Cell (2009) 0.75

Track record? Pigment Cell Melanoma Res (2012) 0.75

Research - endure! Pigment Cell Melanoma Res (2011) 0.75

MITF--past, present and future. Pigment Cell Melanoma Res (2010) 0.75

It's a small (integrated multidisciplinary) world. Pigment Cell Melanoma Res (2012) 0.75

A darker side to p53. Pigment Cell Res (2007) 0.75

[Ubiquitin system in hypoxia response]. Tanpakushitsu Kakusan Koso (2006) 0.75

A complex but promising therapy. Pigment Cell Melanoma Res (2010) 0.75

It's in our roots. Pigment Cell Melanoma Res (2011) 0.75

Flipping or scrolling. Pigment Cell Melanoma Res (2010) 0.75

Animis opibusque parati. Pigment Cell Melanoma Res (2010) 0.75

Mice enhance their image. Pigment Cell Melanoma Res (2011) 0.75

Melanoma initiating cells - easy as ABC? Pigment Cell Melanoma Res (2008) 0.75

The rush to publish. Pigment Cell Melanoma Res (2011) 0.75